AbbVie Inc.
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Last updated:
Abstract:
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Status:
Grant
Type:
Utility
Filling date:
23 Mar 2020
Issue date:
4 May 2021